MDxHealth (NASDAQ:MDXH – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Earnings and Valuation
This table compares MDxHealth and Nyxoah”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MDxHealth | $90.05 million | 2.02 | -$38.07 million | ($0.64) | -6.00 |
| Nyxoah | $4.89 million | 34.90 | -$64.10 million | ($2.49) | -2.01 |
Volatility and Risk
MDxHealth has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for MDxHealth and Nyxoah, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MDxHealth | 1 | 0 | 4 | 0 | 2.60 |
| Nyxoah | 1 | 0 | 3 | 0 | 2.50 |
MDxHealth currently has a consensus target price of $7.75, suggesting a potential upside of 101.82%. Nyxoah has a consensus target price of $12.67, suggesting a potential upside of 152.83%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than MDxHealth.
Profitability
This table compares MDxHealth and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MDxHealth | -30.50% | -1,078.01% | -20.05% |
| Nyxoah | -1,457.97% | -101.99% | -66.74% |
Summary
MDxHealth beats Nyxoah on 8 of the 12 factors compared between the two stocks.
About MDxHealth
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.
